MacroGenics, Inc.

NASDAQ:MGNX

Biotechnology

Healthcare
$1.98 +2.02%

+$0.08 today

Market cap
$126.54M
Beta
1.20
P/E (TTM)
-3.6
EPS (TTM)
-$1.11
52W Low $1.19High $4.64

Volume 0.93M

Average 0.98M

Returns on capital

MacroGenics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-134.2%

avg -52.9%

ROIC

-33.0%

avg -43.6%

ROA

-29.1%

avg -29.4%

Analysis

ROA is currently the strongest return metric at -29.1% versus its period average of -29.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Eric Blasius Risser

Chief Executive Officer, President & DirectorUSD 977.47K530<0.01%

Ezio Bonvini

Senior Vice President of Research & Chief Scientific OfficerUSD 881.4K7280.00K0.13%

James Karrels

Senior VP & CFOUSD 845.55K590<0.01%

Araba Lamouse-Smith

Vice President of Technical Operations————

Frank George Perabo FEBU

Vice President & Interim Head of Clinical Development—62——

Harish Krishnaswamy

Senior Vice President of Business Development & Portfolio Planning————

Jeffrey Stuart Peters

Senior VP, Corporate Secretary, General Counsel & Corporate Compliance Officer—550<0.01%

Beth Smith

Vice President, Controller & Treasurer—58——

Steve Harig

Senior Vice President of Human Resources————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 6, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

1

$129,085.75

Net Transaction Value

−$129,085.75

Net selling

Most Active

Peters Jeffrey Stuart

1 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Aug 19, 26

Peters Jeffrey Stuart

Direct

Sell$129.1K

Summary

Insiders reported 0 buys worth $0.00 and 1 sells worth $129,085.75 over the last 12 months. That adds up to net selling of $129,085.75. Peters Jeffrey Stuart was the most active insider with 1 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A-0.1%
-4.8% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Recent growth has been strongest in Revenue at -0.1% over three years. Forward estimates point to Revenue at -4.8% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does MacroGenics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about MGNX's management, answered from reported figures.

Who manages MGNX?

MacroGenics, Inc. (MGNX) lists 9 active executives. The top listed executive is Araba Lamouse-Smith, Vice President of Technical Operations.

Are MGNX insiders buying or selling?

Recent insider activity shows net buying of $4.68M.